Optimization of anti-solvent crystallization process of sulbactam sodium

doi:10.16085/j.issn.1000-6613.2018-2126

Abstract

Abstract:

At present, the way of purifying sulbactam sodium is to synthesize sulbactam sodium by sulbactam acid, which is obtained by reduction reaction. The method is time-consuming, labor-intensive and requires a large variety of drugs and reagents, and is not energy-saving and environmentally friendly. For this problem, the orthogonal experiment $L 27 313$ was used to optimize the anti-solvent crystallization of sulbactam sodium. The effects of six factors and three interactions on crystal size distribution, purity and comprehensive scores of the two were considered, included aging time (A), volume of anti-solvent used(B), volume fraction of ethanol in the anti-solvent(C), rate of addition of the anti-solvent (D), stirring rate (E), crystallization temperature(F), and the interaction between the aging time and the volume of the anti-solvent (A×B), the interaction between the aging time and the volume fraction of ethanol in the decanting agent (A×C), the interaction between the volume of the anti-solvent used and the volume fraction of ethanol in the anti-solvent(B×C) . The results of variance analysis showed: the used volume of anti-solvent (B) has the most significant effect on crystal size distribution(CSD), but other factors and interactions are not significant; the volume fraction of ethanol in the anti-solvent(C), the dropping rate of the anti-solvent(D), the stirring rate (E) and the interaction between the aging time and the volume fraction of ethanol in the anti-solvent(A×C) have a highly significant impact on the purity, and both of interaction between the crystallization time and the volume of the anti-solvent(A×B), and the interaction between the volume of anti-solvent used and the volume fraction of ethanol in the anti-solvent(B×C) have a significant effect, but the others are not significant; when the significant level α is between 0.10 and 0.025, considering the purity-CSD at a ratio of 70% and 30% respectively, volume of the anti-solvent used(B) and the volume fraction of ethanol in the anti-solvent(C) are highly significant, and others are not significant. The optimal operating level combination is A ₂ B ₂ C ₁ D ₃ E ₃ F ₂. Repeated validation tests yielded: the purity of sulbactam sodium raw material can be increased from 79.58% to over 97% by only once anti-solvent crystallization, and the crystal size distribution D[4,3] can be increased from 41.1μm to above 290μm. The mass fraction yield of sulbactam sodium obtained by multiple confirmatory experiments is about 84%. It is found that the impurity sulbactam penicillamine has a certain influence on the particle size distribution of sulbactam sodium. On the basis of solving the original problems, the sulbactam sodium product with suitable particle size distribution can also provide convenience for the subsequent preparation process.

Key words: sulbactam sodium, anti-solvent crystallization, orthogonal test, purity, crystal size distribution

摘要：

目前舒巴坦钠粗品的提纯采用还原成舒巴坦酸后再经反应结晶合成舒巴坦钠的方式，耗时耗力且所需药品、试剂种类较多，不节能环保。针对该问题，采用正交实验 $L 27 313$ 对舒巴坦钠的溶析结晶工艺进行优化，探明了6个因素6个交互作用对粒度、纯度以及两者的综合评分的影响，包括养晶时间（A）、溶析剂用量（B）、溶析剂中乙醇的体积分数（C）、溶析剂的滴加速率（D）、搅拌速率（E）、温度（F）以及养晶时间分别与溶析剂用量（A×B）、与溶析剂中乙醇的体积分数（A×C）的交互作用、溶析剂用量与溶析剂中乙醇的体积分数的交互作用（B×C），并得到了一组最优方案A ₂ B ₂ C ₁ D ₃ E ₃ F ₂。通过该方案可获得纯度x>97%，体积平均粒度D[4,3]≈290μm，质量收率约为84%的舒巴坦钠产品，并发现杂质舒巴坦青霉胺对舒巴坦钠的粒度分布有一定的影响。在解决原有问题的基础上，合适粒度分布的舒巴坦钠产品也可为后续制剂工艺提供方便。

关键词: 舒巴坦钠, 溶析结晶, 正交实验, 纯度, 晶体粒度分布

CLC Number:

TQ028

Li LI, Baoshu LIU, Xueming ZHENG, Hua SUN. Optimization of anti-solvent crystallization process of sulbactam sodium[J]. Chemical Industry and Engineering Progress, 2019, 38(06): 2905-2914.

李丽, 刘宝树, 郑学明, 孙华. 舒巴坦钠溶析结晶工艺优化[J]. 化工进展, 2019, 38(06): 2905-2914.

Figures/Tables 18

水平

养晶时间

溶析剂

用量/mL

溶析剂中乙醇的体积分数/%

滴加速率

/mL·min^-1

搅拌速度

/r·min^-1

温度/℃

序号	A	B	A×B	A×B	C	A×C	A×C	B×C	D	空白	B×C	E	F	D[4,3]/μm	x/%	综合评分
1	1	1	1	1	1	1	1	1	1	1	1	1	1	77.50	99.1576	76.74
2	1	1	1	1`	2	2	2	2	2	2	2	2	2	125.00	95.3440	78.18
3	1	1	1	1	3	3	3	3	3	3	3	3	3	21.70	97.1945	70.50
4	1	2	2	2	1	1	1	2	2	2	3	3	3	145.00	99.0681	82.55
5	1	2	2	2	2	2	2	3	3	3	1	1	1	135.00	94.0519	78.13
6	1	2	2	2	3	3	3	1	1	1	2	2	2	158.00	93.9219	80.04
7	1	3	3	3	1	1	1	3	3	3	2	2	2	141.00	98.6865	81.93
8	1	3	3	3	2	2	2	1	1	1	3	3	3	183.00	96.4820	84.02
9	1	3	3	3	3	3	3	2	2	2	1	1	1	174.00	94.6185	81.93
10	2	1	2	3	1	2	3	1	2	3	1	2	3	178.00	94.3386	82.08
11	2	1	2	3	2	3	1	2	3	1	2	3	1	114.00	99.1497	79.91
12	2	1	2	3	3	1	2	3	1	2	3	1	2	64.90	96.1809	73.54
13	2	2	3	1	1	2	3	2	3	1	3	1	2	345.00	98.8351	99.77
14	2	2	3	1	2	3	1	3	1	2	1	2	3	142.00	96.2244	80.28
15	2	2	3	1	3	1	2	1	2	3	2	3	1	138.00	96.5311	80.15
16	2	3	1	2	1	2	3	3	1	2	2	3	1	205.00	98.9170	87.66
17	2	3	1	2	2	3	1	1	2	3	3	1	2	181.00	94.5988	82.52
18	2	3	1	2	3	1	2	2	3	1	1	2	3	140.00	97.5186	81.02
19	3	1	3	2	1	3	2	1	3	2	1	3	2	164.00	99.0285	84.17
20	3	1	3	2	2	1	3	2	1	3	2	1	3	95.40	95.7996	75.93
21	3	1	3	2	3	2	1	3	2	1	3	2	1	147.00	94.7566	79.68
22	3	2	1	3	1	3	2	2	1	3	3	2	1	159.00	98.9166	83.66
23	3	2	1	3	2	1	3	3	2	1	1	3	2	218.00	94.5893	85.73
24	3	2	1	3	3	2	1	1	3	2	2	1	3	125.00	97.4810	79.69
25	3	3	2	1	1	3	2	3	2	1	2	1	3	185.00	94.2366	82.61
26	3	3	2	1	2	1	3	1	3	2	3	2	1	216.00	93.9306	85.09
27	3	3	2	1	3	2	1	2	1	3	1	3	2	110.00	97.5640	78.44

因素	$K 1 j ˉ$	$K 2 j ˉ$	$K 3 j ˉ$	$S j$
A	128.91	167.54	157.711	7256.007
B	109.72	173.89	170.556	23487.500
A×B	139.13	145.100	169.93	4802.807
A×B	151.133	152.27	150.77	11.007
C	177.72	156.600	119.844	15440.869
A×C	137.311	172.556	144.300	6268.176
A×C	131.39	143.767	179.011	10989.769
B×C	157.833	156.378	139.96	1774.269
D	132.756	165.667	155.744	5130.242
空白	174.167	151.211	128.79	9266.569
B×C	148.722	142.93	162.511	1820.802
E	153.644	156.222	144.300	708.309
F	151.722	167.43	135.011	4731.902

因素	$K 1 j ˉ$	$K 2 j ˉ$	$K 3 j ˉ$	$S j$
A	128.91	167.54	157.711	7256.007
B	109.72	173.89	170.556	23487.500
A×B	139.13	145.100	169.93	4802.807
A×B	151.133	152.27	150.77	11.007
C	177.72	156.600	119.844	15440.869
A×C	137.311	172.556	144.300	6268.176
A×C	131.39	143.767	179.011	10989.769
B×C	157.833	156.378	139.96	1774.269
D	132.756	165.667	155.744	5130.242
空白	174.167	151.211	128.79	9266.569
B×C	148.722	142.93	162.511	1820.802
E	153.644	156.222	144.300	708.309
F	151.722	167.43	135.011	4731.902

方差来源	S_j	f	$S j ˉ$	F_j	F-theory	显著性
A	7256.007	2	3628.003	1.84	2.62-3.54-4.56
B	23487.500	2	11743.750	5.95		**
C	15440.869	2	7720.434	3.91		*
D ^△	5130.242	2	2565.121	1.30
E ^△	708.309	2	354.154	0.18
F ^△	4731.902	2	2365.951	1.20
A×B ^△	4813.813	4	1203.453	0.61	2.29-2.93-3.61
A×C	17257.944	4	4314.486	2.19
B×C ^△	3595.071	4	898.768	0.46
e	9266.569	2	4633.284	2.35
$e Δ$	35501.913	18	1972.329

方差来源	S_j	f	$S j ˉ$	F_j	F-theory	显著性
A	7256.007	2	3628.003	1.84	2.62-3.54-4.56
B	23487.500	2	11743.750	5.95		**
C	15440.869	2	7720.434	3.91		*
D ^△	5130.242	2	2565.121	1.30
E ^△	708.309	2	354.154	0.18
F ^△	4731.902	2	2365.951	1.20
A×B ^△	4813.813	4	1203.453	0.61	2.29-2.93-3.61
A×C	17257.944	4	4314.486	2.19
B×C ^△	3595.071	4	898.768	0.46
e	9266.569	2	4633.284	2.35
$e Δ$	35501.913	18	1972.329

因素	$K 1 j ˉ$	$K 2 j ˉ$	$K 3 j ˉ$	$S j$
A	96.50	96.92	96.26	2.039
B	96.77	96.62	96.28	1.130
A×B	97.08	95.83	96.77	7.678
A×B	96.56	96.41	96.72	0.430
C	97.91	95.57	96.20	26.319
A×C	96.83	96.42	96.43	0.978
A×C	97.41	96.48	95.79	11.842
B×C	96.16	97.42	96.09	10.094
D	97.02	95.34	97.32	20.426
空白	96.52	96.75	96.41	0.564
B×C	96.34	96.67	96.66	0.634
E	96.11	95.96	97.61	15.087
F	96.67	96.53	96.48	0.172

因素	$K 1 j ˉ$	$K 2 j ˉ$	$K 3 j ˉ$	$S j$
A	96.50	96.92	96.26	2.039
B	96.77	96.62	96.28	1.130
A×B	97.08	95.83	96.77	7.678
A×B	96.56	96.41	96.72	0.430
C	97.91	95.57	96.20	26.319
A×C	96.83	96.42	96.43	0.978
A×C	97.41	96.48	95.79	11.842
B×C	96.16	97.42	96.09	10.094
D	97.02	95.34	97.32	20.426
空白	96.52	96.75	96.41	0.564
B×C	96.34	96.67	96.66	0.634
E	96.11	95.96	97.61	15.087
F	96.67	96.53	96.48	0.172

方差来源	S	f	$S ˉ$	F_j	F-theory	显著性
A	2.039	2	1.019	3.28	5.14-7.26-10.90
B^△	1.130	2	0.565
C	26.319	2	13.160	42.32		**
D	20.426	2	10.213	32.84		**
E	15.087	2	7.543	24.26		**
F^△	0.172	2	0.086
A×B	8.108	4	2.027	6.52	4.53-6.23-9.15	*
A×C	12.820	4	3.205	10.31		**
B×C	10.727	4	2.682	8.62		*
e	0.546	2	0.282
$e Δ$	1.866	6	0.311

方差来源	S	f	$S ˉ$	F_j	F-theory	显著性
A	2.039	2	1.019	3.28	5.14-7.26-10.90
B^△	1.130	2	0.565
C	26.319	2	13.160	42.32		**
D	20.426	2	10.213	32.84		**
E	15.087	2	7.543	24.26		**
F^△	0.172	2	0.086
A×B	8.108	4	2.027	6.52	4.53-6.23-9.15	*
A×C	12.820	4	3.205	10.31		**
B×C	10.727	4	2.682	8.62		*
e	0.546	2	0.282
$e Δ$	1.866	6	0.311

项目	C ₁	C ₂	C ₃	K_iA	a_i
A ₁	D ₁₁=296.91	D ₁₂=285.88	D ₁₃=285.73	868.53	-0.06
A ₂	D ₂₁=292.09	D ₂₂=289.97	D ₂₃=290.23	872.29	0.36
A ₃	D ₃₁=292.18	D ₃₂=284.32	D ₃₃=289.80	866.30	-0.30
K_iC	881.18	860.17	865.77	2607.12
c_j	1.35	-0.99	-0.36

项目	C ₁	C ₂	C ₃
A ₁	1.21	-0.22	-0.89
A ₂	-0.91	0.72	0.19
A ₃	-0.21	-0.50	0.71

项目	C ₁	C ₂	C ₃	K_iB	b_i
B ₁	292.52	290.29	288.13	870.95	0.21
B ₂	296.82	284.87	287.93	869.62	0.06
B ₃	291.84	285.01	289.70	866.55	-0.28
K_iC	881.18	860.17	865.77	2607.12
c_j	1.35	-0.99	-0.36

项目	C ₁	C ₂	C ₃
B ₁	-0.61	0.98	-0.36
B ₂	0.97	-0.68	-0.28
B ₃	-0.35	-0.29	0.65

因素	$K 1 j ˉ$	$K 2 j ˉ$	$K 3 j ˉ$	$S j$
A	79.34	82.99	81.67	61.63
B	77.86	83.33	82.80	164.14
A×B	80.63	80.27	83.09	42.58
A×B	81.31	81.30	81.39	0.04
C	84.57	81.09	78.33	176.14
A×C	80.30	83.07	80.62	41.40
A×C	80.19	80.61	83.19	47.54
B×C	81.61	82.37	80.01	26.28
D	80.03	81.71	82.25	23.98
空白	83.28	81.45	79.26	72.98
B×C	80.95	80.68	82.37	14.92
E	81.21	81.33	81.46	0.28
F	81.44	82.70	79.85	36.73

因素	$K 1 j ˉ$	$K 2 j ˉ$	$K 3 j ˉ$	$S j$
A	79.34	82.99	81.67	61.63
B	77.86	83.33	82.80	164.14
A×B	80.63	80.27	83.09	42.58
A×B	81.31	81.30	81.39	0.04
C	84.57	81.09	78.33	176.14
A×C	80.30	83.07	80.62	41.40
A×C	80.19	80.61	83.19	47.54
B×C	81.61	82.37	80.01	26.28
D	80.03	81.71	82.25	23.98
空白	83.28	81.45	79.26	72.98
B×C	80.95	80.68	82.37	14.92
E	81.21	81.33	81.46	0.28
F	81.44	82.70	79.85	36.73

方差来源	S	f	$S ˉ$	F _j	F-theory	显著性
A $Δ$	61.63	2	30.82		2.62-3.54-4.56
B	164.14	2	82.07	5.29		*
C	176.14	2	88.07	5.67		*
D $Δ$	23.98	2	11.99
E $Δ$	0.28	2	0.14
F $Δ$	36.73	2	18.37
A×B $Δ$	42.62	4	10.65		2.29-2.93-3.61
A×C $Δ$	88.94	4	22.24	1.43		不显著
B×C $Δ$	41.20	4	10.30
e	72.98	2	36.49
$e Δ$	279.43	18	15.52

方差来源	S	f	$S ˉ$	F _j	F-theory	显著性
A $Δ$	61.63	2	30.82		2.62-3.54-4.56
B	164.14	2	82.07	5.29		*
C	176.14	2	88.07	5.67		*
D $Δ$	23.98	2	11.99
E $Δ$	0.28	2	0.14
F $Δ$	36.73	2	18.37
A×B $Δ$	42.62	4	10.65		2.29-2.93-3.61
A×C $Δ$	88.94	4	22.24	1.43		不显著
B×C $Δ$	41.20	4	10.30
e	72.98	2	36.49
$e Δ$	279.43	18	15.52

References 35

1	程晓军, 刘安祥, 宋守忠 . β-内酰胺类抗生素发展浅述[J]. 中国药业, 2001, 10(2): 64-66.
2	CHENG X J , LIU A X , SONG S Z . The development of β-lactam antibiotics[J]. China Pharmaceuticals, 2001, 10(2): 64-66.
3	蔡文辉, 张文莉, 付英梅, 等 . β-内酰胺酶抑制剂研究进展[J]. 中国抗生素杂志, 2013, 38(11): 805-809.
	CAI W H , ZHANG W L , FU Y M , et al . Advances in β-lactamase inhibitors[J]. Chinese Journal of Antibiotics, 2013, 38(11): 805-809.
4	茹仁萍, 武谦虎 . 抗感染药物临床合理应用手册[M]. 北京: 中国医药科技出版社, 2016: 246.
	RU R P , WU Q H . Handbook of clinical rational use of anti-infective drugs[M]. Beijing: Chinese Medical Science and Technology Press, 2016: 246.
5	陈兴娟, 侯秀梅, 曹欣祥, 等 . 舒巴坦的工艺优化研究[J]. 化学中间体, 2007 (2): 30-36.
	CHEN X J , HOU X M , CAO X X , et al . Research of the optimizing process of sulbactam[J]. Chemical Intermediate, 2007 (2): 30-36.
6	邱方利, 潘富友 . 舒巴坦钠的合成[J]. 化学世界, 2006, 47(2): 99-101.
	QIU F L , PAN F Y . Synthesis of sulbactam sodium[J]. Chemical World, 2006, 47(2): 99-101.
7	程宏辉, 谢朝晖 . 舒巴坦钠合成工艺的研究[J]. 化学设计通讯, 2001, 27(2): 61-62.
	CHENG H H , XIE Z H . Study of the synthesis of sulbactam sodium[J]. Chemical Design Communications, 2001, 27(2): 61-62.
8	姜浩伟 . 舒巴坦钠结晶工艺的改进[J]. 制剂技术, 2011, 20(8): 48.
	JIANG H W . Improvement of sulbactam sodium crystallization process[J]. Formulation Technology, 2011, 20(8): 48.
9	吕烨, 刘彦 . 舒巴坦钠结晶工艺的改进[J]. 黑龙江医药, 2006, 19(3): 185-186.
	LÜ Y , LIU Y . Improvement of crystallization of sulbactam sodium[J]. Heilongjiang Medicine Jourrnal, 2006, 19(3): 185-186.
10	淄博鑫泉医药技术服务有限公司 . 舒巴坦钠的制备方法: CN10669974[P]. 2017-05-24.
	Zibo Xinquan Pharmaceutical Technology Service Co., Ltd. . Process for preparation of sulbactam sodium: CN106699774[P]. 2017-05-24.
11	杜海生, 李凤侠, 赵振华, 等 . 反应结晶制备高质量的舒巴坦钠[J]. 山东化工, 2009, 38(4): 18-19.
	DU H S , LI F X , ZHAO Z H , et al . A prosess of preparing high quanlity sulbactam sodium by reacting crystallization[J]. Shandong Chemical Industry, 2009, 38(4): 18-19.
12	国家药典委员会 . 中华人民共和国药典[M]. 北京:中国医药科技出版社, 2015:1423.
	National Pharmacopoeia Commission . People’s Republic of China pharmacopoeia[M]. Beijing: Chinese Medical Science and Technology Press, 2015: 1423.
13	巴艳, 林悦凤 . 基础医学与临床.2[M]. 济南: 山东大学出版社, 2016: 188.
	BA Y , LIN Y F . Basic medicine and clinical.2[M]. Jinan: Shandong University Press, 2016:188.
14	胡延维, 孙芸 . 舒巴坦钠结晶过程中的影响因素分析[J]. 苏州大学学报(医学版), 2003, 23(6): 674-676.
	HU Y W , SUN Y . Analysis of factors influencing sulbactam sodium crystallization process[J]. Suzhou University Journal of Medical Science, 2003, 23(6): 674-676.
15	颜青, 肖永红, 何绥平 . 必须重视β-内酰胺类抗生素与其酶抑制剂复方制剂的科学开发[J]. 中国临床药学杂志, 2007, 16(4): 259-261 .
	YAN Q , XIAO Y H , HE S P . Scientific development of compound preparations of β-lactam antibiotics and their enzyme inhibitors[J]. Chinese Journal of Clinical Pharmacy, 2007, 16(4): 259-261.
16	龚俊波, 陈明洋, 黄翠, 等 . 面向清洁生产的制药结晶[J]. 化工学报, 2015, 66(9): 3271-3278.
	GONG J B , CHEN M Y , HUANG C , et al . Clean production of pharmaceutical crystallization[J]. CIESC Journal, 2015, 66(9): 3271-3278.
17	MULLIN J W . Crystallization[M]. 4th ed. Oxford: Reed Educational and Professional Publishing, 2001.
18	KIM H J, YEO S D . Liquid antisolvent crystallization of griseofulvin from organic solutions[J]. Chemical Engineering Research and Design, 2015, 97: 68-76.
19	刘敏, 李玉兰, 杨敏, 等 . 高效液相色谱法测定舒巴坦钠的有关物质[J]. 中国药师, 2005, 8(6): 469-472.
	LIU M , LI Y L , YANG M , et al . HPLC determination of related substances in sulbactam sodium[J]. China Pharmacist, 2005, 8(6): 469-472.
20	李玉兰,刘敏, 王玉 . 舒巴坦钠中舒巴坦青霉胺杂质含量测定方法的建立[J]. 中国药师, 2005, 8(6): 467-469.
	LI Y L , LIU M , WANG Y . Establishment of a method for the impurity determination of sulbactam penicillamine in sulbactam sodium[J]. China Pharmacist, 2005, 8(6): 467-469.
21	胡大为, 胡小芳, 林丽莹 . 粉体粒度分布分形维数与流动性及硬脂酸镁改进流动性关系[J]. 中国粉体技术, 2007, 13(4): 1-4.
	HU D W , HU X F , LIN L Y . Correlation of powders’ particle size distribution fractal with flow ability and flow addition reagent magnesium stearate[J]. China Powder Technology, 2007, 13(4): 1-4.
22	刘瑞江, 张业旺, 闻崇炜 . 正交试验设计和分析方法研究[J]. 实验技术与管理, 2010, 27(9): 52-55.
	LIU R J , ZHANG Y W , WEN C W . Study on the design and analysis methods of orthogonal experiment[J]. Experimental Technology and Management, 2010, 27(9): 52-55.
23	马博爱, 龚俊波 . 阿奇霉素二水合物溶析结晶工艺优化[J]. 化学工业与工程, 2015, 32(1): 37-40.
24	MA B A, GONG J B . Optimization of crystallization process of azithromyc in dihydrate[J]. Chemical Industryand Engineering, 2015, 32(1): 37-40.
25	王海蓉, 张春桃, 王永莉 . 加晶种控制头孢曲松钠溶析结晶产品粒度分布的研究[J]. 中国抗生素杂志, 2009, 34(6): 337-340.
	WANG H R , ZHANG C T , WANG Y L . Stuudies on the control of crystal size distribution of ceftriaxone sodium in dilution crystallization by seeding[J]. Chinese Journal of Antibiotics, 2009, 34(6): 337-340.
26	尹永恒, 鲍颖, 王永莉, 等 . 诱导头孢噻肟钠结晶过程研究[J]. 化学工业与工程, 2014, 31(2): 48-53.
	YIN Y H , BAO Y , WANG Y L , et al . Induced crystallization of cefotaxime sodium[J]. Chemical Industry and Engineering, 2014, 31(2): 48-53.
27	刘宝树 . 5'-鸟苷酸二钠溶析结晶过程研究[D]. 天津: 天津大学, 2007.
	LIU B S . Study on crystallization process of disodium 5'-guanylate[D]. Tianjin: Tianjin University, 2007.
28	WANG H Y , WARD J D . Seeding and optimization of batch reactive crystallization[J]. Industrial and Engineering Chemistry Research, 2015, 54(38): 9360-9368.
29	李永曙, 刘继阳, 梅丽琴, 等 . 注射用美洛西林钠溶析结晶工艺研究[J]. 中国抗生素杂志, 2010, 35(5):353-356.
	LI Y S , LIU J Y , MEI L Q , et al . Study on solvent-out crystallization process of mezlocillin sodium for injection[J]. Chinese Journal of Antibiotics, 2010, 35(5): 353-356.
30	鲍颖 . 盐酸大观霉素溶析结晶过程研究[D]. 天津:天津大学, 2003.
	BAO Y . Study on the process of dilution crystallization of spectinomycin dihydrochloride[D]. Tianjin: Tianjin University, 2003.
31	孙华 . 洛伐他汀结晶过程研究[D]. 天津: 天津大学, 2006.
	SUN H . Study on the crystallization process of lovastatin[D]. Tianjin: Tianjin University, 2006.
32	庄楚强, 何春雄 . 应用数理统计基础[M]. 广州: 华南理工大学出版社, 2011: 222-284.
	ZHUANG C Q , HE C X . Applied mathematical statistics foundation[M]. Guangzhou: South China University of Technology Publishing House, 2011: 222-284.
33	王雪雁 . 一种治疗传染性疾病的舒巴坦钠化合物及其制备方法: CN10486946[P]. 2015-04-30.
	WANG X Y . Sulbactam sodium compound for treating infectious disease and its preparing : CN10486946[P]. 2015-04-30.
34	张丕德, 龙晓英 . 正交设计与数据分析在药学研究中的应用(Ⅱ)[J]. 广东药学院学报, 2009, 25(6): 648-657.
	ZHANG P D , LONG X Y . Application of orthogonal design and data analysis in pharmaceutical research (Ⅱ)[J]. Journal of Guangdong Pharmaceutical College, 2009, 25(6): 648-657.
35	陈翔, 梁卫玖 . 建立Excel宏快速处理正交试验设计数据[J]. 中国卫生检验杂志, 2009, 19(11): 2696-2697.
	CHEN X , LIANG W J . Establish Excel macro to quickly process orthogonal experimental design data[J]. Chinese Journal of Health Laboratory Technology, 2009, 19(11): 2696-2697.

[1]	WANG Haoran, YIN Quanyu, FANG Ming, HOU Jianlin, LI Jun, HE Bin, ZHANG Mingyue. Optimization of near critical-water treatment process of tobacco stems [J]. Chemical Industry and Engineering Progress, 2023, 42(9): 5019-5027.
[2]	LI Xiuping, YU Yang, HE Wang, LYU Junhui. High-gravity intensified decarburization process and apparent kinetics of AMP-PZ composite solution [J]. Chemical Industry and Engineering Progress, 2022, 41(S1): 22-28.
[3]	HE Guangli, DOU Meiling. Progress on effect of hydrogen impurities on the performance of automotive fuel cells [J]. Chemical Industry and Engineering Progress, 2021, 40(9): 4815-4822.
[4]	SUN Kai, WANG Wanli, HUANG Qunxing. Effect of typical impurities on the pyrolysis oil of waste plastics [J]. Chemical Industry and Engineering Progress, 2021, 40(6): 3499-3506.
[5]	Xiaomin LIU, Bangqiang ZHANG, Bin AI, Yanmei YANG, Juan WANG, Haibo YANG, Hong CAI, Wei BAO. Development and current status of hydrogen quality standards for proton exchange membrane fuel cell [J]. Chemical Industry and Engineering Progress, 2021, 40(2): 703-708.
[6]	HE Xuefeng, LIU Bo, ZHANG Shengen. Current status of control technology of Fe impurity in recycled aluminum alloy [J]. Chemical Industry and Engineering Progress, 2021, 40(10): 5251-5269.
[7]	Weiwei LI, Xiaofeng XIE, Shubo WANG. Performance degradation analysis of solid polymer electrolyte water electrolysis [J]. Chemical Industry and Engineering Progress, 2020, 39(S2): 168-174.
[8]	Meng LI,Xuedong LIU,Shichun ZHU,Lanjian YU,Jing XU. Application of ultrasound in cathode materials of ternary lithium ion batteries [J]. Chemical Industry and Engineering Progress, 2020, 39(2): 635-642.
[9]	Xinyu LIU, Lingbo LI, Baozhong LI, Hongshan GUO. Progress in purification and reclamation of metamorphic amine [J]. Chemical Industry and Engineering Progress, 2020, 39(10): 4200-4209.
[10]	Junli ZHANG, Junbo GONG, Hua SUN, Zhigang DUAN, Weiguo HU. Study and application of the continuous crystallization process of cefalexin [J]. Chemical Industry and Engineering Progress, 2019, 38(07): 3349-3354.
[11]	LÜ Donghui, LIU Guilian. Impurity-deficit based graphical method for integrating water network with regeneration reuse [J]. Chemical Industry and Engineering Progress, 2019, 38(04): 1671-1680.
[12]	Shuaiwei GU, Yuxing LI, Lin TENG, Cailin WANG, Qihui HU, Datong ZHANG, Xiao YE, Jinghan WANG. Decompression and temperature drop characteristics of small-scale supercritical CO₂ pipeline leakage with small holes [J]. Chemical Industry and Engineering Progress, 2019, 38(02): 805-812.
[13]	Yingchun CHEN, Jiafen ZHOU, Guimin LU, Jianguo YU. A review on the production technologies of high-purity magnesia and magnesium oxide ceramics [J]. Chemical Industry and Engineering Progress, 2019, 38(01): 505-515.
[14]	DING Yigang, HAN Yonghong, LUO Wanzhi, LONG Bingwen, YU Ying, JU Li. Size control for the reactive crystallization of potassium dihydrogen [J]. Chemical Industry and Engineering Progress, 2017, 36(10): 3590-3595.
[15]	XIE Yubo, LIU Daoping, YANG Liang, YANG Meng. Experimental study on the growth characteristics of natural gas hydrate formation on suspended gas bubbles in distilled water and tap water [J]. Chemical Industry and Engineering Progree, 2017, 36(01): 129-135.